| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 17376 | 2017 |
| Heart disease and stroke statistics 2005 update American Heart Association http://www. americanheart. org/statistics/, 2005 | 8567* | 2005 |
| Heart disease and stroke statistics—2013 update: a report from the American Heart Association AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, WB Borden, ... Circulation 127 (1), e6-e245, 2013 | 8139 | 2013 |
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin, JS Kim, R Luo, J Feng, S Ye, ... The lancet oncology 10 (1), 25-34, 2009 | 6508 | 2009 |
| Clinical characteristics of 2019 novel coronavirus infection in China W Guan, Z Ni, Y Hu, W Liang, C Ou, J He, L Liu, H Shan, C Lei, DSC Hui, ... MedRxiv, 2020 | 2258 | 2020 |
| Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project W Au, DD Weisenburger, T Intragumtornchai, S Nakamura, WS Kim, I Sng, ... Blood, The Journal of the American Society of Hematology 113 (17), 3931-3937, 2009 | 826 | 2009 |
| Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study J Lee, C Suh, YH Park, YH Ko, SM Bang, JH Lee, DH Lee, J Huh, SY Oh, ... Journal of clinical oncology 24 (4), 612-618, 2006 | 744 | 2006 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 743 | 2018 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 682 | 2019 |
| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma LH Sehn, AF Herrera, CR Flowers, MK Kamdar, A McMillan, M Hertzberg, ... Journal of Clinical Oncology 38 (2), 155, 2020 | 677 | 2020 |
| Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study … M Yamaguchi, YL Kwong, WS Kim, Y Maeda, C Hashimoto, C Suh, ... J Clin Oncol 29 (33), 4410-4416, 2011 | 667 | 2011 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 661 | 2022 |
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study J Lee, SH Park, HM Chang, JS Kim, HJ Choi, MA Lee, JS Chang, ... The lancet oncology 13 (2), 181-188, 2012 | 545 | 2012 |
| Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project DD Weisenburger, KJ Savage, NL Harris, RD Gascoyne, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (12), 3402-3408, 2011 | 493 | 2011 |
| SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group YL Kwong, WS Kim, ST Lim, SJ Kim, T Tang, E Tse, AYH Leung, CS Chim Blood, The Journal of the American Society of Hematology 120 (15), 2973-2980, 2012 | 449 | 2012 |
| An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection … S Kim, DH Lim, J Lee, WK Kang, JS MacDonald, CH Park, SH Park, ... International Journal of Radiation Oncology* Biology* Physics 63 (5), 1279-1285, 2005 | 443 | 2005 |
| Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. U Vitolo, M Trněný, D Belada, JM Burke, AM Carella, N Chua, ... Journal of clinical oncology: official journal of the American Society of …, 2017 | 421 | 2017 |
| Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium … SJ Kim, K Kim, BS Kim, CY Kim, C Suh, J Huh, SW Lee, JS Kim, J Cho, ... | 401 | 2009 |
| A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma HY Yoo, MK Sung, SH Lee, S Kim, H Lee, S Park, SC Kim, B Lee, K Rho, ... Nature genetics 46 (4), 371-375, 2014 | 389 | 2014 |
| The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma S Park, J Lee, YH Ko, A Han, HJ Jun, SC Lee, IG Hwang, YH Park, JS Ahn, ... Blood, The Journal of the American Society of Hematology 110 (3), 972-978, 2007 | 382 | 2007 |
Seok Jin KimSamsung Medical Center, Sungkyunkwan University School of MedicineVerified email at skku.edu
